Contact
searchSearch
HMP Global
Login
Quiz

Autologous Hematopoietic Cell Transplantation or CAR-T Therapy for Patients With Relapsed LBCL

09/30/2024

Related Content

Sarah Rutherford, MD
Videos
Emerging Strategies to Reshape Frontline Treatment of Diffuse Large B-Cell Lymphoma
04/01/2026
Sarah Rutherford, MD
Sarah Rutherford, MD, discusses recent advances in frontline treatment of diffuse large B-cell lymphoma and how emerging data are reshaping clinical practice.
Sarah Rutherford, MD, discusses recent advances in frontline treatment of diffuse large B-cell lymphoma and how emerging data are reshaping clinical practice.
Sarah Rutherford, MD, discusses...
04/01/2026
Oncology
Julio Chavez, MD
Videos
Evolving Treatment Strategies for Patients With Relapsed or Refractory DLBCL
03/19/2026
Julio Chavez, MD
Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.
Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.
Julio Chavez, MD, reviews...
03/19/2026
Oncology
Olalekan Oluwole, MD, MBBS
Conference Coverage
Evaluating Benefits of Outpatient vs Inpatient CAR T-Cell Therapy at Newly Authorized Treatment Centers
02/11/2026
Olalekan O. Oluwole
Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...
Olalekan Oluwole, MD, MBBS reported results from an observational analysis that outpatient treatment with CAR T-cell therapy was associated with lower healthcare utilization, fewer adverse events, and reduced medical costs compared with...
Olalekan Oluwole, MD, MBBS...
02/11/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology

Recent News

News
Sintilimab Plus Anlotinib Demonstrates Promise in Relapsed/Refractory Small Cell Lung Cancer
04/02/2026
Stephanie Holland
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial suggest that sintilimab plus anlotinib demonstrates encouraging efficacy with manageable safety among patients with relapsed/refractory small cell lung cancer (SCLC) who have a short chemotherapy-free...
Results from a phase 2 trial...
04/02/2026
Oncology
News
Adebrelimab Plus Chemotherapy Maintains Long-Term Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3 CAPSTONE-1 trial demonstrate that adebrelimab plus chemotherapy continues to provide durable survival benefit in patients with extensive-stage small cell lung cancer.
Updated results from the phase 3...
04/02/2026
Oncology
News
Lurbinectedin Plus Atezolizumab Delays Subsequent Therapy and Maintains Survival Benefit in ES-SCLC
04/02/2026
Stephanie Holland
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the phase 3 IMforte trial suggest that first-line treatment with lurbinectedin plus atezolizumab delays subsequent therapy and maintains overall survival benefit in patients with extensive-stage small cell lung cancer.
Exploratory results from the...
04/02/2026
Oncology
FDA Approval
FDA Approves Brexucabtagene Autoleucel for R/R Mantle Cell Lymphoma
04/02/2026
Stephanie Holland
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase 2 ZUMA-2 study, the FDA approved brexucabtagene autoleucel for adult patients with relapsed/refractory mantle cell lymphoma, including those who are BTK inhibitor–naïve.
Based on results from the phase...
04/02/2026
Oncology
News
Consolidation Serplulimab Following Hypo-cCRT Improves Outcomes in Limited-Stage Small Cell Lung Cancer
04/02/2026
Emily Estrada
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2 ASTRUM-LC01 trial demonstrate that following concurrent Hypo-cCRT with consolidation serplulimab improves survival with manageable safety in limited-stage small cell lung cancer.
Updated results from the phase 2...
04/02/2026
Oncology
News
Izalontamab Brengitecan Plus Serplulimab Demonstrates Strong Promise in Treatment-Naïve ES-SCLC
04/01/2026
Emily Estrada
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the phase 2 BL-B01D1-204-01 study, izalontamab brengitecan plus serplulimab demonstrated encouraging efficacy with manageable safety in treatment- extensive-stage small cell lung cancer.
According to results from the...
04/01/2026
Oncology
News
Transdermal Estradiol Noninferior to LHRH Agonists in Locally Advanced Prostate Cancer
04/01/2026
Stephanie Holland
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study demonstrated that transdermal estradiol was noninferior to luteinizing hormone-releasing hormone agonists for survival outcomes among patients with locally advanced prostate cancer.
Results from a phase 3 study...
04/01/2026
Oncology
News
Etrumadenant-Based Chemoimmunotherapy Improves Survival in Metastatic Colorectal Cancer
04/01/2026
Emily Estrada
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9 study, demonstrate that etrumadenant plus zimberelimab, mFOLFOX-6, and bevacizumab significantly improves survival in heavily pretreated patients with metastatic colorectal cancer.
Results from the phase 2 ARC-9...
04/01/2026
Oncology
News
Distinct Immune Microenvironment Associated With Long-Term Survival in High-Grade Glioma
03/31/2026
Emily Estrada
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational analysis suggest that long-term survival in patients with high-grade glioma is associated with a distinct immune microenvironment characterized by enhanced NK cell activity and microglial activation.
Results from a translational...
03/31/2026
Oncology
News
Ruxolitinib Plus Venetoclax Demonstrates Safe but Limited Clinical Activity in Relapsed/Refractory AML
03/31/2026
Emily Estrada
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter, phase 1 trial demonstrated that ruxolitinib plus venetoclax is well tolerated but shows modest clinical activity in heavily pretreated relapsed/refractory acute myeloid leukemia.
Results from a multicenter,...
03/31/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use